Table 4 Articles used for Aβ and p-tau OR analyses in the Cognitively unimpaired (CU) group
CU population A+T+ vs. A-T- | ||||||
|---|---|---|---|---|---|---|
Study | Centre/cohort | Measurement technique (cut-offs) | Subjects (n.) | Age (mean (SD) / median (range)) | Follow-up time (months) | |
Mean (SD) | Median (range) | |||||
ADNI | ADNI | amyloidPET (SUVR >1.11), CSF Aβ42 (<977 pg/mL); CSF p-tau181 (>23 pg/mL) | 334 | 72.9 (6.3) | 69 (48) | 54 |
Ebenau, 2020 | ADC (Amsterdam Dementia Cohort, SCIENCe! Subjective Cognitive Impairment Cohort) | amyloidPET (v.r.), CSF Aβ42 (<<813 pg/mL); CSF p-tau181 (>52 pg/mL) | 216 | 60.0 (9.0) | 36 (24) | n.d.a |
Ossenkoppele, 2022 | BioFINDER-1, BioFINDER-2, HABS | amyloidPET (SUVR >1.03 in BioFINDER-1, -2, DVR >1.2 (>26 CL) in HABS); tauPET (SUVR >1.26 in BioFINDER-1, SUVR >1.34 in BioFINDER-2, SUVR >1.36 in HABS) | 821 | 70.5 (9.8) | 41.8 (18.9) | n.d. |
Strikwerda-Brown, 2022 | AIBL, Knight ADRC, Prevent AD | amyloidPET (24 Centiloids for global Aβ); tauPET (SUVR >1.27 for tau meta-ROI) | 326 | 70.9 (5.6) | n.d. | 39.8 (15.2 – 68.0) |
CU population A+T- vs. A-T- | ||||||
ADNI | ADNI | amyloidPET (SUVR >1.11), CSF Aβ42 (<977 pg/mL); CSF p-tau181 (>23 pg/mL) | 364 | 72.9 (6.3) | 69 (48) | 54 |
Ebenau, 2020 | ADC (Amsterdam Dementia Cohort, SCIENCe! Subjective Cognitive Impairment Cohort) | amyloidPET (v.r.), CSF Aβ42 (<<813 pg/mL); CSF p-tau181 (>52 pg/mL) | 227 | 60.0 (9.0) | 36 (24) | n.d. |
Ossenkoppele, 2022 | BioFINDER-1, BioFINDER-2, HABS | amyloidPET (SUVR >1.03 in BioFINDER-1, -2, DVR >1.2 (>26 CL) in HABS); tauPET (SUVR >1.26 in BioFINDER-1, SUVR >1.34 in BioFINDER-2, SUVR >1.36 in HABS) | 1003 | 70.5 (9.8) | 41.8 (18.9) | n.d. |
Strikwerda-Brown, 2022 | AIBL, Knight ADRC, Prevent AD | amyloidPET (24 Centiloids for global Aβ); tauPET (SUVR >1.27 for tau meta-ROI) | 387 | 70.9 (5.6) | n.d. | 39.8 (15.2 – 68.0) |